Novexel: Broad spectrum spinout

Novexel S.A., which spun out of sanofi-aventis SA last week, will seek to capitalize on an anti-infectives pipeline and capabilities inherited from the Aventis side of the pharma merger. In addition to infrastructure and experienced personnel, the company has two compounds in Phase I trials and about 18 projects in earlier stages of R&D.

"There's no particular technology per se here," said CEO Iain Buchanan. "The assets are purely target- and compound-based."

The

Read the full 728 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE